APO Research
Talk to an analyst

APO RESEARCH · REPORT

Preformulation CDMO Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Preformulation CDMO Service Market Outlook and Growth Opportunities 2026

6 January 2026204 pages

Choose your research edition.

Industry ResearchPreformulation CDMO Service Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Preformulation CDMO Service Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Preformulation CDMO Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Preformulation CDMO Service Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Preformulation CDMO Service Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Preformulation CDMO Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Preformulation CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Preformulation CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Preformulation CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Preformulation CDMO Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Preformulation CDMO Service market include Aenova, Ascendia Pharmaceutical, Aurigene Pharmaceutical Services, Corealis Pharma, CritiTech, Crystal Pharmatech, DPT Laboratories, Eirgen Pharma and Eurofins Scientific, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Preformulation CDMO Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Preformulation CDMO Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Preformulation CDMO Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Preformulation CDMO Service market.

Preformulation CDMO Service Segment by Company

Aenova

Ascendia Pharmaceutical

Aurigene Pharmaceutical Services

Corealis Pharma

CritiTech

Crystal Pharmatech

DPT Laboratories

Eirgen Pharma

Eurofins Scientific

Koziatek Consulting

Lonza

Oakwood Labs

Quotient Sciences

Sofpromed

Upperton Pharma Solutions

American Pharmaceutical Review

Bluepharma

Preformulation CDMO Service Segment by Type

Basic Characteristics CDMO Service

Pre-formulation Research CDMO Service

Prototype Formulation Development CDMO Service

Preformulation CDMO Service Segment by Application

Innovative Drug Development

Improved New Drug Development

Generic and Biosimilar Drug Development

Others

Preformulation CDMO Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Preformulation CDMO Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Preformulation CDMO Service key companies, revenue, market share, and recent developments.

3. To split the Preformulation CDMO Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Preformulation CDMO Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Preformulation CDMO Service significant trends, drivers, influence factors in global and regions.

6. To analyze Preformulation CDMO Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Preformulation CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Preformulation CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Preformulation CDMO Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Preformulation CDMO Service industry.

Chapter 3: Detailed analysis of Preformulation CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Preformulation CDMO Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Preformulation CDMO Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Preformulation CDMO Service Industry Trends Table 2. Preformulation CDMO Service Industry Drivers Table 3. Preformulation CDMO Service Industry Opportunities and Challenges Table 4. Preformulation CDMO Service Industry Restraints Table 5. Global Preformulation CDMO Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Preformulation CDMO Service Revenue Share by Company (2021-2026) Table 7. Global Preformulation CDMO Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Preformulation CDMO Service Key Company Manufacturing Base & Headquarters Table 9. Global Preformulation CDMO Service Company, Product Type & Application Table 10. Global Preformulation CDMO Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Preformulation CDMO Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Basic Characteristics CDMO Service Table 15. Significant Companies of Pre-formulation Research CDMO Service Table 16. Significant Companies of Prototype Formulation Development CDMO Service Table 17. Global Preformulation CDMO Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Preformulation CDMO Service Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Preformulation CDMO Service Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Preformulation CDMO Service Sales Value Share by Type (2021-2026) Table 21. Global Preformulation CDMO Service Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Innovative Drug Development Table 23. Significant Companies of Improved New Drug Development Table 24. Significant Companies of Generic and Biosimilar Drug Development Table 25. Significant Companies of Others Table 26. Global Preformulation CDMO Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Preformulation CDMO Service Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Preformulation CDMO Service Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Preformulation CDMO Service Sales Value Share by Application (2021-2026) Table 30. Global Preformulation CDMO Service Sales Value Share by Application (2027-2032) Table 31. Global Preformulation CDMO Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Preformulation CDMO Service Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Preformulation CDMO Service Sales Value Share by Region (2021-2026) Table 34. Global Preformulation CDMO Service Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Preformulation CDMO Service Sales Value Share by Region (2027-2032) Table 36. Global Preformulation CDMO Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Preformulation CDMO Service Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Preformulation CDMO Service Sales Value Market Share by Country (2021-2026) Table 39. Global Preformulation CDMO Service Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Preformulation CDMO Service Sales Value Market Share by Country (2027-2032) Table 41. Aenova Company Information Table 42. Aenova Business Overview Table 43. Aenova Preformulation CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Aenova Preformulation CDMO Service Product Portfolio Table 45. Aenova Recent Development Table 46. Ascendia Pharmaceutical Company Information Table 47. Ascendia Pharmaceutical Business Overview Table 48. Ascendia Pharmaceutical Preformulation CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Ascendia Pharmaceutical Preformulation CDMO Service Product Portfolio Table 50. Ascendia Pharmaceutical Recent Development Table 51. Aurigene Pharmaceutical Services Company Information Table 52. Aurigene Pharmaceutical Services Business Overview Table 53. Aurigene Pharmaceutical Services Preformulation CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Aurigene Pharmaceutical Services Preformulation CDMO Service Product Portfolio Table 55. Aurigene Pharmaceutical Services Recent Development Table 56. Corealis Pharma Company Information Table 57. Corealis Pharma Business Overview Table 58. Corealis Pharma Preformulation CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Corealis Pharma Preformulation CDMO Service Product Portfolio Table 60. Corealis Pharma Recent Development Table 61. CritiTech Company Information Table 62. CritiTech Business Overview Table 63. CritiTech Preformulation CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. CritiTech Preformulation CDMO Service Product Portfolio Table 65. CritiTech Recent Development Table 66. Crystal Pharmatech Company Information Table 67. Crystal Pharmatech Business Overview Table 68. Crystal Pharmatech Preformulation CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Crystal Pharmatech Preformulation CDMO Service Product Portfolio Table 70. Crystal Pharmatech Recent Development Table 71. DPT Laboratories Company Information Table 72. DPT Laboratories Business Overview Table 73. DPT Laboratories Preformulation CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. DPT Laboratories Preformulation CDMO Service Product Portfolio Table 75. DPT Laboratories Recent Development Table 76. Eirgen Pharma Company Information Table 77. Eirgen Pharma Business Overview Table 78. Eirgen Pharma Preformulation CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Eirgen Pharma Preformulation CDMO Service Product Portfolio Table 80. Eirgen Pharma Recent Development Table 81. Eurofins Scientific Company Information Table 82. Eurofins Scientific Business Overview Table 83. Eurofins Scientific Preformulation CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Eurofins Scientific Preformulation CDMO Service Product Portfolio Table 85. Eurofins Scientific Recent Development Table 86. Koziatek Consulting Company Information Table 87. Koziatek Consulting Business Overview Table 88. Koziatek Consulting Preformulation CDMO Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Koziatek Consulting Preformulation CDMO Service Product Portfolio Table 90. Koziatek Consulting Recent Development Table 91. Lonza Company Information Table 92. Lonza Business Overview Table 93. Lonza Preformulation CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Lonza Preformulation CDMO Service Product Portfolio Table 95. Lonza Recent Development Table 96. Oakwood Labs Company Information Table 97. Oakwood Labs Business Overview Table 98. Oakwood Labs Preformulation CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Oakwood Labs Preformulation CDMO Service Product Portfolio Table 100. Oakwood Labs Recent Development Table 101. Quotient Sciences Company Information Table 102. Quotient Sciences Business Overview Table 103. Quotient Sciences Preformulation CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Quotient Sciences Preformulation CDMO Service Product Portfolio Table 105. Quotient Sciences Recent Development Table 106. Sofpromed Company Information Table 107. Sofpromed Business Overview Table 108. Sofpromed Preformulation CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Sofpromed Preformulation CDMO Service Product Portfolio Table 110. Sofpromed Recent Development Table 111. Upperton Pharma Solutions Company Information Table 112. Upperton Pharma Solutions Business Overview Table 113. Upperton Pharma Solutions Preformulation CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Upperton Pharma Solutions Preformulation CDMO Service Product Portfolio Table 115. Upperton Pharma Solutions Recent Development Table 116. American Pharmaceutical Review Company Information Table 117. American Pharmaceutical Review Business Overview Table 118. American Pharmaceutical Review Preformulation CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. American Pharmaceutical Review Preformulation CDMO Service Product Portfolio Table 120. American Pharmaceutical Review Recent Development Table 121. Bluepharma Company Information Table 122. Bluepharma Business Overview Table 123. Bluepharma Preformulation CDMO Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Bluepharma Preformulation CDMO Service Product Portfolio Table 125. Bluepharma Recent Development Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Preformulation CDMO Service Product Image Figure 2. Global Preformulation CDMO Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Preformulation CDMO Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Preformulation CDMO Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Basic Characteristics CDMO Service Image Figure 8. Pre-formulation Research CDMO Service Image Figure 9. Prototype Formulation Development CDMO Service Image Figure 10. Global Preformulation CDMO Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Preformulation CDMO Service Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Preformulation CDMO Service Sales Value Share by Type (2021-2032) Figure 13. Innovative Drug Development Image Figure 14. Improved New Drug Development Image Figure 15. Generic and Biosimilar Drug Development Image Figure 16. Others Image Figure 17. Global Preformulation CDMO Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Preformulation CDMO Service Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Preformulation CDMO Service Sales Value Share by Application (2021-2032) Figure 20. Global Preformulation CDMO Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Preformulation CDMO Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Preformulation CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 23. North America Preformulation CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Preformulation CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Preformulation CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Preformulation CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Preformulation CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Preformulation CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 29. South America Preformulation CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Preformulation CDMO Service Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Preformulation CDMO Service Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Preformulation CDMO Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Basic Characteristics CDMO Service
  • Pre-formulation Research CDMO Service
  • Prototype Formulation Development CDMO Service
Applications
  • Innovative Drug Development
  • Improved New Drug Development
  • Generic and Biosimilar Drug Development
  • Others
Companies covered
  • Aenova
  • Ascendia Pharmaceutical
  • Aurigene Pharmaceutical Services
  • Corealis Pharma
  • CritiTech
  • Crystal Pharmatech
  • DPT Laboratories
  • Eirgen Pharma
  • Eurofins Scientific
  • Koziatek Consulting
  • Lonza
  • Oakwood Labs
  • Quotient Sciences
  • Sofpromed
  • Upperton Pharma Solutions
  • American Pharmaceutical Review
  • Bluepharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Preformulation CDMO Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Preformulation CDMO Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Preformulation CDMO Service Market Dynamics
  1. 2.1 Preformulation CDMO Service Industry Trends
  2. 2.2 Preformulation CDMO Service Industry Drivers
  3. 2.3 Preformulation CDMO Service Industry Opportunities and Challenges
  4. 2.4 Preformulation CDMO Service Industry Restraints
3 Preformulation CDMO Service Market by Company
  1. 3.1 Global Preformulation CDMO Service Company Revenue Ranking in 2025
  2. 3.2 Global Preformulation CDMO Service Revenue by Company (2021-2026)
  3. 3.3 Global Preformulation CDMO Service Company Ranking (2024-2026)
  4. 3.4 Global Preformulation CDMO Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Preformulation CDMO Service Company Product Type and Application
  6. 3.6 Global Preformulation CDMO Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Preformulation CDMO Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Preformulation CDMO Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Preformulation CDMO Service Market by Type
  1. 4.1 Preformulation CDMO Service Type Introduction
  2. 4.1.1 Basic Characteristics CDMO Service
  3. 4.1.2 Pre-formulation Research CDMO Service
  4. 4.1.3 Prototype Formulation Development CDMO Service
  5. 4.2 Global Preformulation CDMO Service Sales Value by Type
  6. 4.2.1 Global Preformulation CDMO Service Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Preformulation CDMO Service Sales Value by Type (2021-2032)
  8. 4.2.3 Global Preformulation CDMO Service Sales Value Share by Type (2021-2032)
5 Preformulation CDMO Service Market by Application
  1. 5.1 Preformulation CDMO Service Application Introduction
  2. 5.1.1 Innovative Drug Development
  3. 5.1.2 Improved New Drug Development
  4. 5.1.3 Generic and Biosimilar Drug Development
  5. 5.1.4 Others
  6. 5.2 Global Preformulation CDMO Service Sales Value by Application
  7. 5.2.1 Global Preformulation CDMO Service Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Preformulation CDMO Service Sales Value by Application (2021-2032)
  9. 5.2.3 Global Preformulation CDMO Service Sales Value Share by Application (2021-2032)
6 Preformulation CDMO Service Regional Value Analysis
  1. 6.1 Global Preformulation CDMO Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Preformulation CDMO Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Preformulation CDMO Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Preformulation CDMO Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Preformulation CDMO Service Sales Value (2021-2032)
  7. 6.3.2 North America Preformulation CDMO Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Preformulation CDMO Service Sales Value (2021-2032)
  10. 6.4.2 Europe Preformulation CDMO Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Preformulation CDMO Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Preformulation CDMO Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Preformulation CDMO Service Sales Value (2021-2032)
  16. 6.6.2 South America Preformulation CDMO Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Preformulation CDMO Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Preformulation CDMO Service Sales Value Share by Country, 2025 VS 2032
7 Preformulation CDMO Service Country-level Value Analysis
  1. 7.1 Global Preformulation CDMO Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Preformulation CDMO Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Preformulation CDMO Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Preformulation CDMO Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Preformulation CDMO Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Preformulation CDMO Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Preformulation CDMO Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Aenova
  2. 8.1.1 Aenova Company Information
  3. 8.1.2 Aenova Business Overview
  4. 8.1.3 Aenova Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Aenova Preformulation CDMO Service Product Portfolio
  6. 8.1.5 Aenova Recent Developments
  7. 8.2 Ascendia Pharmaceutical
  8. 8.2.1 Ascendia Pharmaceutical Company Information
  9. 8.2.2 Ascendia Pharmaceutical Business Overview
  10. 8.2.3 Ascendia Pharmaceutical Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ascendia Pharmaceutical Preformulation CDMO Service Product Portfolio
  12. 8.2.5 Ascendia Pharmaceutical Recent Developments
  13. 8.3 Aurigene Pharmaceutical Services
  14. 8.3.1 Aurigene Pharmaceutical Services Company Information
  15. 8.3.2 Aurigene Pharmaceutical Services Business Overview
  16. 8.3.3 Aurigene Pharmaceutical Services Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Aurigene Pharmaceutical Services Preformulation CDMO Service Product Portfolio
  18. 8.3.5 Aurigene Pharmaceutical Services Recent Developments
  19. 8.4 Corealis Pharma
  20. 8.4.1 Corealis Pharma Company Information
  21. 8.4.2 Corealis Pharma Business Overview
  22. 8.4.3 Corealis Pharma Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Corealis Pharma Preformulation CDMO Service Product Portfolio
  24. 8.4.5 Corealis Pharma Recent Developments
  25. 8.5 CritiTech
  26. 8.5.1 CritiTech Company Information
  27. 8.5.2 CritiTech Business Overview
  28. 8.5.3 CritiTech Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CritiTech Preformulation CDMO Service Product Portfolio
  30. 8.5.5 CritiTech Recent Developments
  31. 8.6 Crystal Pharmatech
  32. 8.6.1 Crystal Pharmatech Company Information
  33. 8.6.2 Crystal Pharmatech Business Overview
  34. 8.6.3 Crystal Pharmatech Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Crystal Pharmatech Preformulation CDMO Service Product Portfolio
  36. 8.6.5 Crystal Pharmatech Recent Developments
  37. 8.7 DPT Laboratories
  38. 8.7.1 DPT Laboratories Company Information
  39. 8.7.2 DPT Laboratories Business Overview
  40. 8.7.3 DPT Laboratories Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 DPT Laboratories Preformulation CDMO Service Product Portfolio
  42. 8.7.5 DPT Laboratories Recent Developments
  43. 8.8 Eirgen Pharma
  44. 8.8.1 Eirgen Pharma Company Information
  45. 8.8.2 Eirgen Pharma Business Overview
  46. 8.8.3 Eirgen Pharma Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eirgen Pharma Preformulation CDMO Service Product Portfolio
  48. 8.8.5 Eirgen Pharma Recent Developments
  49. 8.9 Eurofins Scientific
  50. 8.9.1 Eurofins Scientific Company Information
  51. 8.9.2 Eurofins Scientific Business Overview
  52. 8.9.3 Eurofins Scientific Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Eurofins Scientific Preformulation CDMO Service Product Portfolio
  54. 8.9.5 Eurofins Scientific Recent Developments
  55. 8.10 Koziatek Consulting
  56. 8.10.1 Koziatek Consulting Company Information
  57. 8.10.2 Koziatek Consulting Business Overview
  58. 8.10.3 Koziatek Consulting Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Koziatek Consulting Preformulation CDMO Service Product Portfolio
  60. 8.10.5 Koziatek Consulting Recent Developments
  61. 8.11 Lonza
  62. 8.11.1 Lonza Company Information
  63. 8.11.2 Lonza Business Overview
  64. 8.11.3 Lonza Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Lonza Preformulation CDMO Service Product Portfolio
  66. 8.11.5 Lonza Recent Developments
  67. 8.12 Oakwood Labs
  68. 8.12.1 Oakwood Labs Company Information
  69. 8.12.2 Oakwood Labs Business Overview
  70. 8.12.3 Oakwood Labs Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Oakwood Labs Preformulation CDMO Service Product Portfolio
  72. 8.12.5 Oakwood Labs Recent Developments
  73. 8.13 Quotient Sciences
  74. 8.13.1 Quotient Sciences Company Information
  75. 8.13.2 Quotient Sciences Business Overview
  76. 8.13.3 Quotient Sciences Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Quotient Sciences Preformulation CDMO Service Product Portfolio
  78. 8.13.5 Quotient Sciences Recent Developments
  79. 8.14 Sofpromed
  80. 8.14.1 Sofpromed Company Information
  81. 8.14.2 Sofpromed Business Overview
  82. 8.14.3 Sofpromed Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Sofpromed Preformulation CDMO Service Product Portfolio
  84. 8.14.5 Sofpromed Recent Developments
  85. 8.15 Upperton Pharma Solutions
  86. 8.15.1 Upperton Pharma Solutions Company Information
  87. 8.15.2 Upperton Pharma Solutions Business Overview
  88. 8.15.3 Upperton Pharma Solutions Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Upperton Pharma Solutions Preformulation CDMO Service Product Portfolio
  90. 8.15.5 Upperton Pharma Solutions Recent Developments
  91. 8.16 American Pharmaceutical Review
  92. 8.16.1 American Pharmaceutical Review Company Information
  93. 8.16.2 American Pharmaceutical Review Business Overview
  94. 8.16.3 American Pharmaceutical Review Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  95. 8.16.4 American Pharmaceutical Review Preformulation CDMO Service Product Portfolio
  96. 8.16.5 American Pharmaceutical Review Recent Developments
  97. 8.17 Bluepharma
  98. 8.17.1 Bluepharma Company Information
  99. 8.17.2 Bluepharma Business Overview
  100. 8.17.3 Bluepharma Preformulation CDMO Service Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Bluepharma Preformulation CDMO Service Product Portfolio
  102. 8.17.5 Bluepharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst